Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
D-1553 Combined With IN10018 in Subjects With Locally Advanced or Metastatic Solid Tumors With KRAS G12C Mutation
NCT06166836Phase 2Active, not recruiting
- Sponsor
- InxMed
- Start
- Oct 2022
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of garsorasib, ifebemtinib in solid tumor, colorectal cancer (CRC), non-small cell lung cancer (NSCLC), sponsored by InxMed. Started Oct 2022; status: active, not recruiting.
02
Drugs
garsorasibifebemtinib
03
Conditions
solid tumorcolorectal cancer (CRC)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06166836.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06166836.